In gene expression profiling studies of lung cancer cell lines to study therapeutic drug sensitivity, PLAU and CDH1 have been suggested as novel biomarkers of cetuximab sensitivity [28], and TGM2 was suggested as a potential marker of doxorubicin sensitivity [27]. Here, TGM2 is linked to lung carcinoma.